Search the Newsreel

Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q2 Revenue $0.4M, vs. FactSet Est of $533K

Pulse Biosciences, Inc. (PLSE) reported its Q2 revenue at $0.4 million, falling short of FactSet's estimated $533K. The company's stock, PLSE, is listed on Nasdaq in the Advanced Medical Equipment & Technology sector. The article also highlights recent news, including their Q2 earnings call, …

Pulsenmore (PLSM) investors back six proposals at 2026 AGM

Pulsenmore Ltd. (PLSM) announced that its shareholders approved all six proposals presented at the 2026 Annual General Meeting held on August 6, 2026. These proposals were previously detailed in the Notice of Annual General Meeting dated July 1, 2026, which was furnished to the …

Pulse Biosciences earnings on deck as PFA technology faces test By Investing.com

Pulse Biosciences Inc. is expected to report its second-quarter results after market close on Thursday, with investors keenly watching the performance of its Nanosecond Pulsed Field Ablation (PFA) technology. Analysts anticipate a loss of 29 cents per share on revenue of $533,330, reflecting sequential …

Gulshan Polyols షేర్ దూకుడు: Q1 FY27 లో లాభాల్లో **307%** జంప్! కారణం ఏంటంటే..

Pulse Biosciences (PLSE) Q2 Revenue Miss Highlights Market's Hig

(PLSE) Movement as an Input in Quant Signal Sets

This article from Stock Traders Daily discusses Pulse Biosciences Inc (NASDAQ: PLSE), highlighting strong sentiment across all horizons and compelling upside potential. It presents three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, tailored for different …

UL Solutions Inc. (NYSE: ULS) CEO sells 12,500 shares under 10b5-1 plan

UL Solutions Inc. CEO Jennifer F. Scanlon sold 12,500 shares of Class A Common Stock on August 3, 2026, through three open-market transactions. These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted in December 2025. The shares were sold at weighted-average …

UL Solutions posts strong Q2 results and outlook

UL Solutions Inc. (ULS) reported strong Q2 2026 financial results with revenue up 5.2% to $816 million and net income surging 161.9% to $254 million. The company reaffirmed its full-year 2026 outlook, expecting mid-single-digit organic revenue growth and an adjusted EBITDA margin near 27%. …

Why Pulse Biosciences (PLSE) Is Up 6.4% After NANOPULSE-AF Trial Hits Enrollment Midpoint And What It Means

Pulse Biosciences (PLSE) saw its stock rise 6.4% after its NANOPULSE-AF pivotal study for atrial fibrillation reached its enrollment midpoint, demonstrating rapid recruitment and clinician enthusiasm for its nPulse System. This milestone provides clearer insight into future pivotal data, which could impact reimbursement and …

Pulsenmore Ltd. Revenue Breakdown – BOATS:PLSM

This article provides a revenue breakdown for Pulsenmore Ltd. (BOATS:PLSM), highlighting that the largest contribution to its revenue came from Israel, which accounted for $2.85 million USD last year and $2.49 million USD the year prior. The report focuses on the company's financial segments …

Is UL Solutions (ULS) Stock A Bargain Or Fully Priced?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. UL Solutions stock has delivered a 22.0% gain over the past year, yet the current checks suggest it no longer looks obviously cheap, with the market price …

UL Solutions Inc. 2026 Q2 Financial Results: Revenue, Net Income, and Comprehensive Financial Overview

UL Solutions Inc. has released its unaudited condensed consolidated financial statements for Q2 2026, reporting strong financial performance. The company achieved a net income of $246 million and diluted EPS of $1.21 for the quarter, alongside consistent dividend payments. With a strong balance sheet …

[10-Q] UL Solutions Inc. Quarterly Earnings Report

UL Solutions Inc. has released its unaudited quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details significant financial activities including a pending €575 million acquisition in Electrical and Electronics Testing, a completed $202 million divestiture of its Employee …

Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview

Pulse Biosciences Inc (PLSE) is expected to report a loss of 36 cents per share, according to this earnings preview. The article from Reuters indicates this forecast without providing further details on the company's financial performance or future outlook.

Why Pulse Seismic Inc stock is tanking today

UL Solutions (NYSE:ULS) Issues Earnings Results, Beats Expectations By $0.03 EPS

UL Solutions Inc. (ULS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, UL Solutions Inc. (ULS) reported revenue of $816 million, up 5.2% over the same period last year. EPS came in at $0.59, compared to $0.52 in the year-ago quarter. The reported revenue represents a surprise of +0.51% over …

UL Solutions Inc. Q2 Income Rises

(RTTNews) - UL Solutions Inc. (ULS) released a profit for its second quarter that Increases, from last year The company's earnings came in at $246 million, or $1.21 per share. This compares with $91 million, or $0.45 per share, last year. Excluding items, UL …

UL Solutions’s (NYSE:ULS) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

UL Solutions's (NYSE:ULS) Q2 CY2026 Earnings Results: Revenue In Line With Expectations Safety certification company UL Solutions (NYSE:ULS) met Wall Street's revenue expectations in Q2 CY2026, with sales up 5.2% year on year to $816 million. Its non-GAAP profit of $0.59 per share was …

UL Solutions Inc. Reports Strong Second Quarter 2026 Results

Second Quarter 20261 Strong revenue growth of 5.2% to $816 million, including 6.6% organic revenue growth Net income of $254 million increased 161.9%, Adjusted Net Income of $129 million increased 17.3%. Net income margin of 31.1% increased 1,860 basis points Diluted earnings per share …

Pulse Biosciences stock hits 52-week high at 36.79 USD By Investing.com

Pulse Biosciences Inc. (PLSE) stock hit a new 52-week high of $36.79, reflecting a 138% return over the past year and 156% year-to-date gains. Despite this performance, InvestingPro analysis suggests the stock might be overvalued, noting high volatility and unlikelihood of profitability this year. …

What To Expect From UL Solutions’s (ULS) Q2 Earnings

What To Expect From UL Solutions's (ULS) Q2 Earnings Safety certification company UL Solutions (NYSE:ULS) will be reporting results this Tuesday before market open. Here's what you need to know. UL Solutions beat analysts' revenue expectations last quarter, reporting revenues of $758 million, up …

Enterprise value to EBITDA forward of Pulse Biosciences, Inc – NASDAQ:PLSE

This article provides the enterprise value to EBITDA forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It also lists the company's trading information on the Nasdaq Stock Market and provides links to its financials, documents, news, and other market data.

Pulse Biosciences (PLSE) Passes AF Study Milestone As Investors Weigh An Overvalued Narrative

Pulse Biosciences (PLSE) has reached a significant milestone in its NANOPULSE-AF Study, with its nPulse System for atrial fibrillation quickly passing the enrollment midpoint. This clinical progress has fueled a strong rally in its share price, with substantial returns over the last 7, 90 …

UL Solutions (NYSE:ULS) - Stock Analysis

This article provides a detailed stock analysis of UL Solutions (NYSE: ULS), highlighting its market capitalization, recent price performance, and financial health. It includes analyst price targets, recent news and updates such as new lab openings and certifications for AI-enabled products, and insider transaction …

Gulshan Polyols Limited Revenue Breakdown – NSE:GULPOLY

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

Pulse Biosciences, Inc. announced its participation in Canaccord Genuity's 46th Annual Growth Conference. Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET, with a live and recorded webcast available on the company's investor website. The company will discuss its Nanosecond …

UL Solutions Stock And 2 Legal Services Picks for Rising AI Compliance Demand

The article highlights the growing demand for legal and compliance services due to increasing AI regulation, spurred by security breaches at AI companies like Anthropic and OpenAI. It identifies three stocks—UL Solutions (ULS), Knights Group Holdings (KGH), and IPH (IPH)—as potential beneficiaries. Each company's …

Pulse Biosciences (PLSE.US) squeeze baby squeeze

The user "Papacito" posted a short message about Pulse Biosciences (PLSE.US), suggesting a potential "squeeze." The post was made in the moomoo Community, which offers educational content and discussions for investors. The article briefly mentions leading technology companies and their stock performance.

BlackRock, Inc. (ULS) discloses 8.9% Class A stake in UL Solutions via 13G/A

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.9% in UL Solutions Inc.'s Class A stock, totaling 6,900,553 shares as of June 30, 2026. The filing indicates BlackRock has sole voting power over 6,709,231 shares and sole dispositive power …

PLSE|Pulse Biosciences Inc|Price:34.270|Chg%:-1.200

TradingKey provides a comprehensive stock analysis for Pulse Biosciences Inc (PLSE), highlighting its strong fundamentals, high growth potential, and "Buy" analyst rating. The company's CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology is noted as a key innovation, with high institutional ownership and healthy financial indicators …

Pulse Biosciences (PLSE) Expected to Release Earnings on Thursday

Pulse Seismic (TSX:PSD) Stock Faces Margin Squeeze And Uncovered Dividend

Pulse Biosciences’ Aug. 11 Boston fireside chat will be webcast

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

Pulse Biosciences has announced that its NANOPULSE-AF IDE Pivotal Study, investigating its Nanosecond Pulsed Field Ablation (nano-PFA) technology for atrial fibrillation, has surpassed its enrollment midpoint since commencing in April 2026. The rapid enrollment is attributed to the enthusiasm of investigational sites for the …

Pulse Biosciences Reaches Enrollment Midpoint in NANOPULSE-AF Trial for Cardiac Treatment

Pulse Biosciences announced that its NANOPULSE-AF clinical study has reached its enrollment midpoint for the nPulse Cardiac Catheter System. This pivotal study is evaluating the technology for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The achievement marks a significant step towards potential regulatory approval …